Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line study of MK-7684A plus etoposide/platinum versus atezolizumab plus etoposide/platinum in extensive-stage small cell lung cancer
CTR20221270Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vibostolimab + pembrolizumab, atezolizumab, etoposide in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started Aug 2022; status: active.
02
Drugs
vibostolimab + pembrolizumabatezolizumabetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20221270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221270.